Recommendation from Healthcare and Automobile & Ancillaries
Ratin Biswass / 20 Mar 2025/ Categories: DSIJ_Magazine_Web, DSIJMagazine_App, Hot Chips, Hot Chips, Recommendations
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.
The scrips in this column have been recommended with a 15-day investment horizon in mind and carry high risk. Therefore, investors are advised to take into account their risk appetite before investing, as fundamentals may or may not back the recommendations.[EasyDNNnews:PaidContentStart]
HIKAL LTD
CMP - ₹401.45
BSE CODE 524735
Volume 30,043
Face Value ₹2
Target ₹434 - ₹442
Stoploss ₹373 (CLS)
Hikal Ltd delivers high-quality active ingredients, intermediates, and R&D services to leading global pharmaceutical players, as well as animal health, biotechnology, crop protection, and speciality chemicals. Hikal is the first Indian life sciences company to receive the prestigious Responsible Care® certification from the International Council of Chemical Associations (ICCA). Hikal reported marginal revenue growth, increasing from ₹447.50 crore in Q3FY24 to ₹447.70 crore in Q3FY25. However, its net profit saw a notable 7 per cent year-on-year rise, reaching ₹17.20 crore, reflecting improved operational efficiencies despite a subdued revenue increase. The company declared an interim dividend of 30 per cent on its equity shares for the financial year 2024-25, reinforcing investor confidence. Following the announcement of its Quarterly Results, the stock witnessed renewed buying interest, climbing over 15 per cent. From a technical perspective, the stock also demonstrates strong upside potential. Hence, we recommend BUY.
Gabriel India Ltd
CMP - ₹570.65
BSE CODE 505714
Volume 3,00,044
Face Value ₹1
Target ₹616 - ₹628
Stoploss ₹531 (CLS)
Gabriel India Ltd, was established in 1961 and has since grown steadily, strengthening its presence across all automotive segments, from two-wheelers to railways. The company has also built a strong foothold across customer segments, including OEMs, aftermarkets, and exports. Gabriel manufactures over 300 models of ride control products, including shock absorbers, dampers, struts, front forks, and others. Considering its financial performance, Gabriel India delivered an impressive 25 per cent revenue growth, rising from ₹815 crore in Q3FY24 to ₹1,017 crore in Q3FY25. Net profit soared by around 46 per cent year-on-year, reaching ₹60 crore. Shares of the company have soared around 40 per cent since the company reported its Q3 performance and still have room for further growth. The company is well-positioned for sustained growth with strong long-term demand across various automotive segments, its leadership position in ride control products, and emerging opportunities in the electric vehicle (EV) sector. Hence, we recommend BUY.
[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]
To read the entire article, you must be a DSIJ magazine subscriber.
[EasyDNNnews:UnPaidContentEnd]